Clinical Trial Update: Re-examination Study of EMEND (Aprepitant) (MK-0869-184)

View source ↗

Summary

A re-examination study of EMEND (aprepitant) completed, with results posted in 2012 evaluating prevention of chemotherapy-induced nausea and vomiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• EMEND (aprepitant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chemotherapy-induced Nausea and Vomiting | Status: COMPLETED | Results posted: 2012-10-05